UID:
almahu_9948025794402882
Format:
1 online resource (411 pages)
ISBN:
1-281-00491-X
,
9786611004910
,
0-08-049044-1
Content:
Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided.KEY FEATURES:* One work that can be consulted for all aspects of anticancer drug development*
Note:
Front Cover; ANTICANCER DRUG DEVELOPMENT; Copyright Page; CONTENTS; CONTRIBUTORS; PREFACE; Chapter 1. A BRIEF HISTORY OF CANCER CHEMOTHERAPY; Summary; 1. Introduction; 2. Genotoxic (Cytotoxic) Therapy; 3. Growth Control Pathways; 4. Host-Tumor Interactions; 5. Conclusions; References; Chapter 2. NOVEL TARGETS IN THE CELL CYCLE AND CELL CYCLE CHECKPOINTS; Summary; 1. Introduction; 2. Molecular Regulation of Cell Cycle Progression; 3. Molecular Regulation of Cell Cycle Checkpoints; 4. Rationale for Targeting Cyclin-Dependent Kinases and Cell Cycle Checkpoint Pathways
,
5. Agents and Strategies for Therapeutic Interference; 6. Conclusions; References; Chapter 3. GROWTH FACTOR AND SIGNAL TRANSDUCTION TARGETS FOR CANCER THERAPY; Summary; 1. Introduction; 2. The ErbB Family of Receptor Tyrosine Kinases (RTKs); 3. The Ras-Raf-MEK-ERK Signaling Pathway; 4. c-Src Kinase, Signal Transduction, Transformation, and Cancer; 5. Akt; 6. Nuclear Hormone Receptors as Targets for Cancer Therapy; 7. Implications for Drug Discovery and Development; References; Chapter 4. CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS; Summary; 1. Introduction
,
2. Two Main Pathways for Drug-Induced Apoptosis; 3. Modulation of Drug-Induced Cell Death by Bcl-2 and Related Proteins; 4. The Central Role of Caspases in Drug-Induced Apoptosis; 5. Synergy between Death Receptors and Cytotoxic Drugs; 6. The Rel/NF-kB/IkB Proteins; 7. Conclusion; References; Chapter 5. DRUG RESISTANCE PATHWAYS AS TARGETS; Summary; 1. Introduction; 2. Targeting Drug Transport; 3. Targeting Cellular Stress Responses; 4. Targeting DNA Repair Systems; 5. Conclusions; References
,
Chapter 6. ROLE OF MATRIX METALLOPROTEINASES AND PLASMINOGEN ACTIVATORS IN CANCER INVASION AND METASTASIS: THERAPEUTIC STRATEGIES; Summary; 1. Introduction; 2. The Extracellular Matrix; 3. Cancer Invasion and Metastasis; 4. Cell Adhesion in Cancer; 5. Cancer Cell Motility; 6. Inflammatory Response to Cancer; 7. Proteolytic Enzymes Implicated in Cancer Invasion; 8. MMPIs as Novel Anticancer Agents; 9. Sheddases; 10. The uPA System: Proteolytic Control of MMP Activation; References; Chapter 7. TUMOR VASCULATURE AS A TARGET; Summary; 1. Introduction; 2. How to Inhibit Tumor Angiogenesis
,
3. Concluding Remarks; References; Chapter 8. GENE-DIRECTED ENZYME PRODRUG THERAPY; Summary; 1. Introduction; 2. Background; 3. Enzyme-Prodrug Systems; 4. Tailored Prodrugs for GDEPT; 5. The Activation Process; 6. Augmenting the Effect; 7. Exploiting the Bystander Effect and Acquired Immunity; 8. Conclusions; References; Chapter 9. TUMOR ANTIGENS AS TARGETS FOR ANTICANCER DRUG DEVELOPMENT; Summary; 1. Introduction; 2. Antigen Targets for Cancer Vaccines; 3. Tumor Antigens as Targets for Antibody-Based Therapeutics; References; Chapter 10. STRUCTURE-BASED DRUG DESIGN AND ITS CONTRIBUTIONS TO CANCER CHEMOTHERAPY
,
English
Additional Edition:
ISBN 0-12-072651-3
Language:
English
